- Change Language: ENGLISH
Let’s give some credit to where credit is due. Our peeps. It has been their hard work and unrelenting energy that has brought the CoolSculpting idea to life. And they are the ones, directly and indirectly, that are about to help you get yours back.
Mark J. Foley
Interim President and Chief Executive Officer
Mark J. Foley has served as interim President and Chief Executive Officer since April 2012. Mr. Foley has also served as Director since 2009 and held the position of Executive Chairman from May 2009 to June 2010. In this role, Mr. Foley had close interaction with all of the different functional areas and participated in decisions regarding the strategic direction of the Company. Mr. Foley has 25 years of medical device operating, investment, board, and CEO experience.
Mr. Foley also currently serves as a Managing Director for RWI Ventures, Executive Chairman for Onpharma, Senior Advisor to TauTona Group, and as a Director for Sonitus Medical and Voyage Medical. His prior experience includes a variety of senior operating roles with large cap companies and venture-backed start-ups such as US Surgical Corporation, Guidant, DVI (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where he was the founder and CEO. Mr. Foley received his B.A. from the University of Notre Dame.
Michael C. Genau
President of North American Franchise (NAF)
Michael C. Genau has served as President of the North American Franchise (NAF) since March 2012. Mr. Genau brings over 20 years of healthcare industry experience to the company. Before joining ZELTIQ, Mr. Genau led Kinetic Concepts, Inc. (KCI) as president of the global Active Healing Solutions business, which represented $1.4B of the company’s revenue. As an officer of KCI, Mr. Genau played a key executive role with the successful sale of company to Apax Partners, a private equity investment group. Prior to that, Mr. Genau worked for GE Healthcare where he held executive and management positions for several key divisions within GE including: Global Diagnostic X-Ray and Mammography, Maternal Infant Care, Clinical Systems, Diagnostic Cardiology and GE Medical Systems Europe. Mr. Genau also served as Executive Vice President and General Manager for Critikon Company, LLC, where he played an instrumental role in the financial turnaround of the business which resulted in the successful sale of Critikon to GE Medical Systems. Earlier in his career, Mr. Genau held sales, marketing, and product management positions for Johnson & Johnson.
Mr. Genau holds a Bachelor of Arts degree in Interdisciplinary Studies from the University of South Carolina.
Joshua T. Brumm
Chief Financial Officer and Senior Vice President
Joshua T. Brumm has served as Chief Financial Officer and Senior Vice President since April 2012. Previously, Mr. Brumm served as Chief Financial Officer and Vice President from January 2012 to April 2012, as Vice President of Corporate Development and Investor Relations from October 2011 to January 2012, as Vice President of of Corporate Development from July 2011 to October 2011, as Senior Managing Director, International Sales and Corporate Development from January 2011 to July 2011, as Director, International Sales and Corporate Development from June 2010 to January 2011, and Director, Corporate Development and Strategy from December 2009 to June 2010. Prior to joining ZELTIQ, Mr. Brumm served as Director of Finance at Proteolix, Inc. from March 2009 to December 2009, at which time it was acquired by Onyx Pharmaceuticals, and as a Healthcare Investment Banking Associate with Citigroup Global Markets, Inc. from June 2007 to March 2009. Prior to June 2007, he served as Chief Executive Officer and Founder of Nu-Ag Distribution, LLC from December 2002 to the company’s sale in June 2007 and as a Healthcare Investment Banking Analyst at Morgan Stanley from May 2001 to August 2002.
Mr. Brumm graduated summa cum laude and holds a B.B.A. from the University of Notre Dame.
Kristine N. Tatsutani, Ph.D.
Chief Technology Officer and Vice President of Enhanced Clinical Outcomes
Kristine N. Tatsutani Ph.D. has served as Chief Technology Officer and Vice President of Enhanced Clinical Outcomes since May 2011. Dr. Tatsutani has 17 years of experience in the field of medical research and medical devices specifically focused in cryogenic applications in oncology, interventional cardiology, electrophysiology, and aesthetic medicine. Prior to joining ZELTIQ, Dr. Tatsutani served as Vice President, Clinical and Scientific Development at MyoScience, Inc., a company developing a cryogenic technology for another aesthetic application, from June 2008 to May 2011. Before that, she held scientific and clinical leadership positions at Boston Scientific from March 2005 to May 2008, and at CryoVascular Systems, Inc. from September 1998 to March 2005. Dr. Tatsutani earned her Ph.D. in Mechanical Engineering, specializing in cryobiology, as well as her Master of Science and Bachelor of Science in Mechanical Engineering at the University of California, Berkeley. She has multiple patents and scientific publications in the field of cryobiology and cryogenic medicine.
Sergio Garcia
Senior Vice President, General Counsel and Corporate Secretary
Sergio Garcia has served as Senior Vice President, General Counsel and Corporate Secretary since April 2012. With more than two decades of legal and compliance experience, Mr. Garcia brings a wealth of expertise and knowledge to the company.
Before joining ZELTIQ, Mr. Garcia was a partner at Reed Smith LLP and Fenwick & West LLP where he advised clients on corporate, transactional, and regulatory compliance matters including corporate governance, strategic transactions, mergers and acquisitions, public disclosure issues, and SEC reporting and compliance. Prior to that, Mr. Garcia played a key role as Vice President, Legal and General Counsel at PDL BioPharma Inc., where he acted as legal advisor to the executive management team and board of directors on a wide range of strategic and operational issues.
Mr. Garcia received his Bachelors of Arts degree from Stanford University and his J.D. law degree from the University of California, Berkeley, School of Law.
Stephen W. Atkinson
Senior Vice President of International
Stephen W. Atkinson has served as Senior Vice President of International since July 2011. Prior to joining ZELTIQ, Mr. Atkinson served from July 2008 to June 2011 as Chief Executive Officer at SYSTAGENIX, a private equity backed wound care company that he carved out from Johnson & Johnson, with direct sales to 15 countries and indirect sales to over 30 more. From 2002 to 2008, Mr. Atkinson served as Area Vice President at CR BARD Inc., a diversified medical device company, where he was responsible for the business in several European countries. Before that, Mr. Atkinson served as Vice President and Managing Director of Europe, Middle East & Africa for Critikon LLC, a private equity backed company that was divested to GE Medical, where he continued to serve as a European Vice President for their Sub-Acute Care, Supplies, and Accessories business. Mr. Atkinson started his career in medical devices with ten years of service at Johnson and Johnson in various sales, marketing, and general management roles. Mr. Atkinson was awarded a B.A. with Honors from the Carnegie School of Leeds Metropolitan University in the United Kingdom, and in 2005 completed the Advanced Executive Program at the Kellogg Business School at Northwestern University in Chicago.
Richard W. Poinsett
Senior Vice President of Operations
Richard W. Poinsett has served as Senior Vice President of Operations since July 2011. Prior to that time, he served as Vice President of Reliability, Integrity and Supply Chain from June 2010 to July 2011, leading our manufacturing, quality assurance, and regulatory initiatives. He also manages the execution of global expansion plans to accelerate our growth in the aesthetic device market. Prior to joining ZELTIQ, Mr. Poinsett served as Vice President of Regulatory Affairs, Quality Assurance and Engineering at Greer Laboratories, Inc. from November 2004 to June 2010; Vice President, Development, Regulatory Affairs and Quality Assurance for In Sound Medical, Inc. from October 2003 to June 2004; and General Manager of REVA Medical, Inc. from September 2000 to December 2003. Prior to REVA Medical, Inc., he held several senior operations management positions at medical device companies. Mr. Poinsett brings over 20 years of senior management experience in operations, R&D, quality assurance, and regulatory affairs to ZELTIQ, primarily in the medical device sector. Mr. Poinsett holds an M.B.A. from Pepperdine University and a B.S. in electrical engineering from Purdue University.
Mark Foley
Director
Mark J. Foley has served on our Board of Directors since July 2009 and has served as the Company’s Executive Chairman of the Board of Directors from July 2009 to May 2010. In this role, Mr. Foley had close interaction with all of the different functional areas and participated in decisions regarding the strategic direction of the Company. Mr. Foley currently serves as a Managing Director of RWI Ventures. While at RWI Ventures, Mr. Foley has led investments in and served on the boards of companies such as BaroSense, Sonitus, and Voyage Medical. Additionally, Mr. Foley serves as Executive Chairman for Onpharma. Prior to joining RWI Ventures in May 2004, Mr. Foley spent 17 years in senior operating roles in both large and start-up medical device companies, most recently founding and serving as Chief Executive Officer of Ventrica, Inc., which was acquired by Medtronic in 2004. Before Ventrica, Inc., Mr. Foley worked for several leading medical device companies, including Perclose (acquired by Abbott), Guidant, DVI (acquired by Eli Lilly), and U.S. Surgical (acquired by Tyco). Mr. Foley received his B.A. from the University of Notre Dame.
Jean George
Director
Jean M. George has served on our Board of Directors since 2005. Ms. George is a General Partner at Advanced Technology Ventures. Ms. George joined the firm in 2002 and serves as the firm’s East Coast lead partner for healthcare investments. Ms. George brings more than 20 years of biopharmaceutical industry experience to the Board, including service at Genzyme Corporation from 1988 to 1998. At Genzyme, Ms. George held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also worked as a Vice President and Founder of Genzyme’s Tissue Repair Division. In 1998, Ms. George joined the venture capital community and was appointed to lead BancBoston Ventures’ life sciences investments. Ms. George is currently a Director of Acceleron Pharmaceuticals, Calithera Biosciences, Hydra Biosciences, and Portola Pharmaceuticals. Ms. George was a Director of Hypnion, Inc. and Proteolix, Inc. Ms. George was named a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. Ms. George holds an M.B.A. degree from Simmons College Graduate School of Management and a B.S. degree from the University of Maine.
Kevin C. O’Boyle
Director
Kevin C. O’Boyle has served on our Board of Directors since July 2011. Mr. O’Boyle serves as Senior Vice President and Chief Financial Officer at Advanced BioHealing, Inc. since December 2010. Previously, Mr. O’Boyle served as the Chief Financial Officer of NuVasive, Inc., a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders, from January 2003 to December 2009 and the Executive Vice President of NuVasive from December 2004 to December 2009. Prior to that time, Mr. O’Boyle served in various positions during his seven years with ChromaVision Medical Systems, Inc., a publicly traded medical device firm specializing in the oncology market, including as its Chief Financial Officer and Chief Operating Officer. Also, Mr. O’Boyle held various positions during his six years with Albert Fisher North America, Inc., a publicly traded international food company, before it was sold in 1996, including Chief Financial Officer and Senior Vice President of Operations. Mr. O’Boyle is currently a member of the Board of Directors of Tornier N.V., a publicly held global orthopedics company, and Genmark Diagnostics, Inc., a publicly traded molecular diagnostics company. Mr. O’Boyle is a CPA and received a B.S. in Accounting from the Rochester Institute of Technology and successfully completed the Executive Management Program at the University of California at Los Angeles, John E. Anderson Graduate Business School.
Bryan Roberts, Ph.D.
Director
Bryan E. Roberts, Ph.D. has served on our Board of Directors since 2005. Dr. Roberts joined Venrock, a venture capital investment firm, in 1997, where he serves as Partner. From 1989 to 1992, Dr. Roberts worked in the corporate finance department of Kidder, Peabody & Co., a brokerage company. Dr. Roberts is currently Chairman of the Board at Ironwood Pharmaceuticals, a publicly traded pharmaceutical company that discovers, develops, and intends to commercialize innovative human medicines, and also serves on the board of directors of several private companies. Dr. Roberts previously served on the board of directors of Athenahealth, Inc., XenoPort, Inc., and Sirna Therapeutics, Inc. Dr. Roberts received a B.A. from Dartmouth College and a Ph.D. in chemistry and chemical biology from Harvard University.
Andrew Schiff, M.D.
Director
Andrew N. Schiff, M.D. has served on our Board of Directors since July 2010. Dr. Schiff joined Aisling Capital in September of 1999 and has served as a Managing Partner since 2002. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at The New York Presbyterian Hospital where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of ARMGO Pharma, Inc., Dynova Laboratories, Inc., Miramar Laboratories, Inc., Planet Technologies, Inc., SkinMedica, Inc., and TransEnterix, Inc. Previously, Dr. Schiff served as a director of Adams Respiratory Therapeutics, Inc., ArgiNOx Pharmaceuticals, Inc., Barrier Therapeutics, Inc., Bioenvision, Inc., Cempra Pharmaceuticals, Inc., CardioKine, Inc., Myogen, Inc., and Sirion Therapeutics, Inc. Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his B.S. with honors in Neuroscience from Brown University.
Jeffrey S. Dover, M.D.
Chairman
Associate Clinical Professor of Dermatology, Yale University School of Medicine. Adjunct Professor of Medicine (Dermatology), Dartmouth Medical School. Director, SkinCare Physicians, Chestnut Hill, MA. www.skincarephysicians.net
Professor of Dermatology, Harvard Medical School. Director, Wellman Center for Photomedicine, Massachusetts General Hospital. www.massgeneral.org/wellman
Director, Massachusetts General Hospital of Dermatology Laser & Cosmetic Center. Faculty Director, Procedural Training in the Department of Dermatology, Harvard Medical School. www.massgeneral.org
Director, Nashville Centre for Laser and Facial Surgery. Clinical Associate Professor, University of Tennessee Health Sciences Center, Memphis, TN. www.drbiesman.com
Assistant Professor, University of Texas Southwestern Medical Center of Dallas. Director, Dallas Medical Skin Care Center, Dallas, TX. www.drburns.net
Clinical Professor, Department of Dermatology, New York University Medical Center. Director, Laser & Skin Surgery Center of New York, NY. www.laserskinsurgery.com
Assistant Clinical Professor of Dermatology, Yale Medical School and Adjunct Assistant Professor of Medicine (Dermatology), Dartmouth Medical School. SkinCare Physicians, Chestnut Hill, MA. www.skincarephysicians.net
Associate Clinical Professor, University of California, Davis, School of Medicine. Director, Laser & Skin Surgery Center of Northern California, Sacramento, CA. www.skinlasers.com
Clinical Instructor, Massachusetts General Hospital Department of Dermatology, Harvard Medical School. Co-owner, Bowes Dermatology, Boca Raton, Florida. www.bowesdermatology.com
Adjunct Clinical Faculty, Cleveland Clinic Florida Department of Plastic Surgery. Founder, Sanctuary Plastic Surgery and Co-owner, Sanctuary Medical Aesthetic Center, Boca Raton, Florida. www.smacboca.com
Clinical Instructor of Dermatology, Johns Hopkins School of Medicine, Baltimore, M.D. Co-Director, Washington Institute of Dermatologic Laser Surgery, Washington, DC. www.skinlaser.com
Adjunct Associate Professor, Dermatology, University of Minnesota Medical School and Director of the Electron Microscopy Laboratory. Director of Zel Skin and Laser Specialists, Edina, Minnesota and Skin Specialists, Minneapolis and Wayzata, MN. www.zelskin.com
Copyright © 2012 ZELTIQ Aesthetics, Inc.
